Produção de vacina BCG recombinante expressando proteína de fusão CMX e avaliação da indução de células B de memória

• Autor(a) principal: Costa Júnior, Abadio de Oliveira da
• Data de Publicação: 2014
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da UFG
• dARK ID: ark:/38995/0013000001tk6
• Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tede/7180
• topic: Tuberculose; BCG; Linfócito B; BCG recombinante; Tuberculosis; BCG; B cells; Recombinant BCG; CIENCIAS BIOLOGICAS::IMUNOLOGIA

Tuberculosis is a global public health problem and despite the recent reduction in the incidence of new cases and deaths worldwide, there are still developing countries where these indices are not so optimistic. The only vaccine recommended to TB by WHO is BCG that, although effective against severe forms of childhood TB, has a questionable efficacy against pulmonary tuberculosis in adults. In the pursue for a molecular improvement for BCG and thus enable the development of a widely used method of prophylaxis, a recombinant BCG was produced by electroporation of BCG Moreau, using three different recombinant plasmid constructions (pLA71, pLA73 and pMIP12), all of them containing the fusion protein CMX coding sequence. However, only the pLA71 transformant expressed the CMX fusion protein in the western blot. In order to evaluate the profile of memory B cells, the specific antibodies against CMX and the efficacy of the vaccine, BALB/c mice were immunized with a single dose of BCG or rBCG-CMX or PBS (control). Serum samples were collected from all animals 30, 60 and 90 days after the immunization and the induction of memory B cells was assessed by flow citometry of the splenocytes cell suspensions. Ninety days after the last immunization, animals were challenged with Mtb H37Rv by the intravenous route and forty five days later, lungs were harvested to analyze the bacterial load and the level of inflammation induced by the infection in immunized mice. Even though no specific antibodies against rCMX, rHspX and rMPT-51 proteins were detected, animals immunized with rBCG-CMX showed specific IgG1 (p<0,0001) and IgG2a (p=0,0007) levels against the BCG culture sediment, higher than those induced in the animals vaccinated with BCG. Besides, the rBCG-CMX vaccine was able to induced delayed long lived memory B cells (p=0,0069), reduced the bacterial load in the lungs (p=0,0041) in a similar way as BCG and generated less tissue damage when compared to BCG Moreau. The recombinant BCG vaccine expressing the CMX fusion protein induced specific antibodies for BCG extract and B cell response to stronger memory than BCG, but, the protection induced by both vaccines (BCG and rBCG) were similar.